SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.
about
Monoclonal antibodies targeting CD38 in hematological malignancies and beyondThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveInterferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target eraAPRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Lysosomal membrane permeabilization in cell death: new evidence and implications for health and disease.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Practical Approaches to the Management of Dual Refractory Multiple Myeloma.Vision Statement for Multiple Myeloma: Future Directions.Monoclonal antibody therapy in multiple myeloma.Immunotherapies targeting CD38 in Multiple Myeloma.Antibody mimicry, receptors and clinical applications.Efficacy and safety of elotuzumab for the treatment of multiple myeloma.Safety issues and management of toxicities associated with new treatments for multiple myeloma.The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.Natural Cyclopeptide RA-XII, a New Autophagy Inhibitor, Suppresses Protective Autophagy for Enhancing Apoptosis through AMPK/mTOR/P70S6K Pathways in HepG2 Cells.Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.Targeting CD38 alleviates tumor-induced immunosuppression.Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistanceOsteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy
P2860
Q26766718-828109DB-AF8D-4D49-B706-267F4F2D015AQ28069789-654C1DCC-16FB-4E06-BD41-0BDF08D0EC06Q33909086-60D2FFEA-471B-4848-9967-D7B9D5F21300Q37035836-412689E7-6242-4277-9369-B70958F39BD1Q38645410-9DAE0457-258D-4E5F-B70F-35B4409FB372Q38672091-C30A1CAE-BAC7-4B91-90EF-22DA355AA705Q38742700-C6577EFC-85C6-4C2A-A651-75E116BFC9CEQ38815409-9B1A9BF8-BC6C-41DC-8BF0-3049F9D6CB57Q38956372-EB70626B-999B-4FCF-A6FF-846C0564A8F6Q39045031-BD285A14-D891-463F-AEE0-E51C53EC976CQ39062940-BCF5E9B4-5BDB-4BDF-8F85-CA8C5831F073Q39070515-8B47058E-5E17-477F-BA79-E15ABFF3BA12Q39100317-520DD5A7-7933-4D86-A425-51A617D0F4C9Q39674450-075EB7F5-EF7C-4A81-929F-4DF9AEC85FFFQ41168758-37ABA361-A746-47AE-996C-292472230FABQ47404057-5D8132DF-B07B-4AF3-81A1-D7731F878830Q47768845-71079508-CDFB-4FAC-9499-5BBD97B11978Q49229364-2164466F-96F8-4361-AFEF-CF6E0FFF2FCAQ51677072-65180B1A-3B25-4039-8821-3D901AB41C8FQ57191729-C2A743B4-3F7E-4B33-98DE-100AF3423489Q58790080-03E84D6C-128D-4658-800F-62E8C39AE8BEQ58804941-43A38902-D8DA-4074-A89E-CDE9307AC13D
P2860
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
SAR650984 directly induces mul ...... ther enhanced by pomalidomide.
@en
type
label
SAR650984 directly induces mul ...... ther enhanced by pomalidomide.
@en
prefLabel
SAR650984 directly induces mul ...... ther enhanced by pomalidomide.
@en
P2093
P2860
P356
P1433
P1476
SAR650984 directly induces mul ...... ther enhanced by pomalidomide.
@en
P2093
K C Anderson
N C Munshi
P2860
P2888
P304
P356
10.1038/LEU.2015.240
P577
2015-09-04T00:00:00Z
P6179
1008077203